The global liquid biopsy market is on a remarkable growth trajectory, with projections indicating an increase from USD 1,538.3 million in 2023 to an astounding USD 10,938.6 million by 2033. This impressive expansion represents a compound annual growth rate (CAGR) of 21.7% over the next decade, underscoring the growing significance of liquid biopsy technology in the healthcare sector.
The surge in market value is primarily driven by the rising incidence of cancer globally and an increasing demand for early and accurate diagnostics. As biomedical research and the pharmaceutical industry intensify their focus on enhancing treatment efficacy, liquid biopsy is emerging as a crucial tool for the early detection of cancers and other pathological conditions.
Traditionally, tumor tissue biopsies have been regarded as the gold standard for cancer characterization and diagnosis. However, their invasive nature and the challenges associated with accessing certain tumors have spurred a shift toward less invasive alternatives. Liquid biopsy, which analyzes genetic material from a simple blood sample, demonstrates significant potential in identifying cancer genetic profiles, monitoring treatment responses, and detecting early signs of therapy resistance.
The market’s growth is further fueled by a rising demand for personalized treatment options. Liquid biopsy’s ability to provide comprehensive genetic analysis through minimally invasive procedures makes it an invaluable resource for tailoring treatments to individual patients’ needs.
Moreover, the increasing accessibility and affordability of liquid biopsy tests contribute to their growing popularity, particularly in emerging economies. In India, for instance, the availability of liquid biopsy tests across numerous laboratories is enhancing access to advanced cancer diagnostics for a broader population. Pioneering companies such as 4baseCare are at the forefront of this transformation, offering affordable and comprehensive genetic testing solutions nationwide.
“Key players in the liquid biopsy market are actively working to reduce costs and expand their distribution networks, especially in emerging markets where cancer rates are on the rise,” says an analyst from Future Market Insights (FMI). “The large population base in these regions presents significant opportunities for market growth, making them a focal point for industry expansion.”
As the global liquid biopsy market continues to evolve, ongoing advancements in technology and accessibility are expected to further cement its role in the fight against cancer, offering new hope and precision in cancer diagnosis and treatment.
Key Takeaways from the Liquid Biopsy Market Report:
- The North America liquid biopsy market is expected to account for a leading share of 50.84%. The United States is predicted to account for 43.8%, enjoying a dominant share in the global and regional markets.
- The Europe market is anticipated to acquire a market share of 19.6% in 2023. Germany holds a prominent share in the region. In 2023, the country is predicted to amass a total of 6.6% share in the global market.
- In Europe, the United Kingdom is predicted to expand at a robust CAGR of 26.4% through 2033.
- In Asia Pacific, China and India display a remarkable percentage of growth, i.e., 29.7% and 24.4%, respectively, through 2033.
- CTC (Circulating Tumor Cells) is projected to obtain a significant market share of 56.9% by biomarker type in 2023.
- By sample type, blood sample type holds prominence in the liquid biopsy market.
Liquid Biopsy Trends on the Rise: Uncover the Full Scope with Our In-Depth Report!
Key Developments by Liquid Biopsy Market Players:
- QIAGEN N.V. (the Netherlands), in May 2022, introduced a therascreen EGFR Plus RGQ PCR Kit, which is a new in vitro diagnostic test for the analysis of sensitive EGFR mutation.
- Guardant Health, Inc., in June 2021, introduced Guardant360 Response test that finds variations in circulating tumor DNA (ctDNA) levels.
- Hoffmann-La Roche Ltd. (Switzerland), in October 2020, gained United States FDA approval for the extended claims for cobas EGFR Mutation Test v2 to be deployed as a companion diagnostic for an extensive range of therapies to manage non-small cell lung cancer (NSCLC).
- Biocept, Inc., in March 2020, agreed with a California-based Independent Physician Association (IPA) to offer its Target Selector liquid assay services to patients and physicians in the network.
Companies Operating in the Liquid Biopsy Market:
- BIOCEPT, INC.
- Qiagen N.V.
- Trovagene, Inc
- Janssen Global Services, LLC
- MDxHealth SA
- Natera, Inc
- F. Hoffmann-La Roche Ltd
- Silicon Biosystems
- Pathway Genomics Corporation
- Sysmex Corporation
- Others
Key Segments Profiled in the Liquid Biopsy Industry Survey:
By Biomarker Type:
- CTCs (Circulating Tumour Cells)
- ctNA (Circulating tumor Nucleic Acids)
- Exosomes
By Sample Type:
- Blood Liquid Biopsy
- Urine Liquid Biopsy
- Other (Plasma, Saliva, CSF) Liquid Biopsy
By Application Type:
- Liquid Biopsy for Lung Cancer
- Liquid Biopsy for Gastrointestinal Cancer
- Liquid Biopsy for Prostate Cancer
- Liquid Biopsy for Breast Cancer
- Liquid Biopsy for Colorectal Cancer
- Liquid Biopsy for Leukemia
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Excluding Japan
- Japan
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
